Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VS vs QNRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

QNRX Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–1 Matrix Metrics)

QNRX Overall Winner 6-Pillar Tally: VS 1 – 2 QNRX (3 Tie) Matrix Metrics: VS 1 – 7 QNRX

As of Nov 20, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) is the stronger overall head-to-head candidate over Versus Systems Inc. (VS) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). VS carries a Unified Composite Score of 40.6/100 (SELL) at $0.57 (N/M Forward P/E, -136.2% operating margin), whereas QNRX carries 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: VS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile QNRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VS vs QNRX
VS NASDAQ
Versus Systems Inc. Common Stock
Services-Computer Processing & Data Preparation
$0.57
-17.44% 1D
Market Cap $4.3M
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 1.45β · 78% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 25.0 Fund 47.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $0.80 · SMA50: $0.95
QNRX NASDAQ Head-to-Head Winner
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.28
-2.35% 1D
Market Cap $16.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.34β · 74% Vol
Unified Composite Score
46.1 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.8%), weak momentum, RSI 32
RSI-14: 32.5 · SMA20: $3.81 · SMA50: $4.64

6-Pillar Scorecard Institutional Category Breakdown (VS 1 – 2 QNRX)

Columns: Metric · VS · QNRX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M 7.6x
PEG Ratio N/M N/M
EV / Revenue 2.8x N/M
2. Growth & Scale QNRX
Revenue Growth (YoY) -24.7% +0.0%
Earnings Growth (YoY) -30.4% +0.0%
TTM Revenue (USD) $1.5M N/A
Market Cap $4.3M $16.1M
3. Profitability & Quality QNRX
Gross Margin 100.0% N/A
Operating Margin -136.2% 0.0%
Net Profit Margin -112.8% 0.0%
Return on Equity (ROE) -69.2% -142.6%
4. Balance Sheet & Cash Flow VS
Cash Generation (TTM) -$2.2M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.82 Book/Sh · -69.2% ROE $5.97 Book/Sh · -142.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VS (1) vs QNRX (7)
Institutional Metric VS QNRX Criterion Row Edge
Market Capitalization
Scale
$4.3M $16.1M Larger Scale QNRX
Trailing P/E Ratio
Valuation
N/M 7.6x Lower Multiple QNRX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-24.7% +0.0% Higher Growth QNRX
Operating Margin (TTM)
Profitability
-136.2% 0.0% Higher Margin QNRX
Net Profit Margin
Profitability
-112.8% 0.0% Higher Margin QNRX
Return on Equity (ROE)
Capital Efficiency
-69.2% -142.6% Higher ROE VS
52-Week Range Position
Momentum
0% ($1–$2) 0% ($3–$24) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.45β · 78% Vol 1.34β · 74% Vol Lower Realized Risk QNRX
Unified Institutional Score
Composite Signal
40.6 / 100 (SELL) 46.1 / 100 (HOLD) Higher Composite QNRX
Trailing 12M Revenue (USD)
Operating Scale
$1.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.2M ($1.82 Book/Sh · -69.2% ROE) N/A ($5.97 Book/Sh · -142.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QNRX +22.63 pp
VS: -40.83% · QNRX: -18.2%
3M Horizon QNRX +16.64 pp
VS: -56.12% · QNRX: -39.48%
6M Horizon QNRX +15.44 pp
VS: -46.68% · QNRX: -31.24%
1Y Horizon VS +22.42 pp
VS: -59.54% · QNRX: -81.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VS vs QNRX. Trailing 12-month operating profitability (VS -136.2% vs QNRX 0.0%) and valuation multiples (VS N/M vs QNRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin100.0%
Op. Margin-136.2%
ROE / Fwd P/E-69.2% · N/M
QNRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-142.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
QNRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QNRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $4.3M market capitalization and -136.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
QNRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $16.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VS vs QNRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) is the stronger overall head-to-head candidate over Versus Systems Inc. (VS) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). VS carries a Unified Composite Score of 40.6/100 (SELL) at $0.57 (N/M Forward P/E, -136.2% operating margin), whereas QNRX carries 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile QNRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

QNRX leads the Growth & Scale pillar: VS posts -24.7% YoY revenue growth and -30.4% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -136.2% operating margin), compared with QNRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VS generates $1.5M in USD-normalized revenue versus N/A for QNRX. In operating R&D and SG&A reinvestment, VS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QNRX.

VS and QNRX trade at balanced relative valuation multiples. VS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (unreported FCF margin), whereas QNRX trades at N/M Forward P/E, 7.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VS (-69.2% ROE) versus QNRX (-142.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 78% Vol realized risk). By comparison, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.